Akari Therapeutics AGM: Director James Neal not re-elected; committee appointments made

Akari Therapeutics Plc

James Neal failed to receive requisite shareholder approval; his directorship ended at AGM conclusion.
Board appointed Dr. Ray Prudo to Audit Committee and Robert Bazemore as Chair of Compensation Committee.
All other 16 resolutions passed, including re-election of five directors and ratification of BDO as auditor.
Shareholders approved issuance of shares under ELOC and warrants from May 20, 2026 private placement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.